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Objectives. We sought to determine the effect of pravastatin on
recurrent cardiovascular events in women with average choles-
terol levels after myocardial infarction (MI).
Background. Little information is available on the effectiveness
of lipid lowering in secondary prevention of coronary heart
disease (CHD) in women; in particular, those with CHD and
average cholesterol levels.
Methods. In the Cholesterol and Recurrent Events (CARE)
trial, 576 postmenopausal women, between 3 and 20 months after
MI, with a total cholesterol level <240 mg/dl and a low density
lipoprotein cholesterol level 115 to 174 mg/dl, were randomized to
receive pravastatin 40 mg/day or matching placebo for a median
follow-up period of 5 years. The main outcome measures were
combined coronary events (coronary death, nonfatal MI, percu-
taneous transluminal coronary angioplasty [PTCA] or coronary
artery bypass graft surgery [CABG]), the primary trial end point
(coronary death or nonfatal MI) and stroke.
Results. Women treated with pravastatin had a risk reduction
of 43% for the primary end point (p 5 0.035), 46% for combined
coronary events (p 5 0.001), 48% for PTCA (p 5 0.025), 40% for
CABG (p 5 0.14) and 56% for stroke (p 5 0.07). The 3,583 men in
the CARE trial also showed a reduction in risk, but the magnitude
tended to be less. Pravastatin improved plasma lipids similarly in
men and women. There were no differences in risk of coronary
events in the placebo group between men and women. Minor
differences between men and women were present in baseline
characteristics and treatment for MI, in general, conferring a
higher risk status and a lower incidence of CABG in the women.
Conclusions. Pravastatin led to significant early reduction of a
wide range of cardiovascular events in post-MI women with
average cholesterol levels.
(J Am Coll Cardiol 1998;32:140–6)
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Although cardiovascular disease remains the major cause of
death in women (1–4), the exclusion or underrepresentation of
women in clinical trials of lipid-lowering treatment has ham-
pered the development of evidence-based standards of care for
women with coronary heart disease (CHD) (5). A total of 402
women were included in secondary prevention trials that used
therapies other than the hydroxymethylglutaryl coenzyme A
(HMG CoA) reductase inhibitors (6–9). Overall, these trends
showed a tendency toward fewer recurrent coronary events in
the women (10,11), although no single trial found a significant
benefit. Thus, guidelines for cholesterol treatment in women
were not evidence based but were extrapolated from data in
men (12,13), or it was recommended that guidelines be de-
ferred (14).
The greater efficacy of HMG CoA reductase inhibitors than
diet or previously available pharmacologic therapies and the
policy of newer secondary prevention trials to enroll women
have provided the much-needed opportunity to investigate
whether contemporary lipid lowering therapy benefits women.
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The Scandinavian Simvastatin Survival (4S) trial demonstrated
that hypercholesterolemic women with a myocardial infarction
(MI) or angina treated with an HMG CoA reductase inhibitor
experienced significant reduction in coronary events (15).
However, the majority of women with CHD do not have
hypercholesterolemia, and information is needed on the effects
of lipid treatment in women with average cholesterol concen-
trations.
The Cholesterol and Recurrent Events (CARE) trial (16)
investigated whether reducing average cholesterol concentra-
tions with pravastatin in patients with an MI would prevent
recurrent cardiac events. It showed that in post-MI patients
with a cholesterol concentration ,240 mg/dl, pravastatin re-
duced the risk of CHD death or recurrent MI by 24% (p 5
0.003), coronary artery bypass graft surgery (CABG) or per-
cutaneous transluminal coronary angioplasty (PTCA) by 27%
(p , 0.001) and stroke by 31% (p 5 0.03). Of the 4,159
patients, 576 were women. Pravastatin therapy reduced the risk
of total coronary events, defined as fatal CHD, nonfatal MI,
CABG and PTCA, by 46% in women (p 5 0.001) and by 20%
in men (p 5 0.001).
The present report sought to determine the effect of
pravastatin on the risk of individual cardiovascular events,
including MI, CABG, PTCA and stroke, in the women and
men in the CARE trial. In addition, their clinical characteris-
tics, including risk factors and severity of coronary disease, and
medical therapies were examined in relation to coronary event
reduction. Finally, we compared the treatment given women
and men with a recent MI in the CARE trial.
Methods
Study design and patients. The design and results of the
CARE trial have been described in detail elsewhere (16,17).
The study was a randomized, double-blind, placebo-controlled
trial with median follow-up period of 5 years and was carried
out in 80 participating centers throughout the United States
and Canada (16). Institutional review board approval was
obtained at all centers. Patients were eligible if they were 21 to
75 years old and had an acute MI between 3 and 20 months
before randomization, a plasma total cholesterol level ,240
mg/dl, a low density lipoprotein (LDL) cholesterol level 115 to
174 mg/dl and a fasting triglyceride level ,350 mg/dl. Women
were required to be post menopausal or surgically sterile. All
participants received diet counseling using the National Cho-
lesterol Education Program Step 1 guidelines (13) and were
randomized to treatment with either pravastatin (40 mg/day)
or matching placebo. The patient was the unit of randomiza-
tion; blinded treatment assignment was given by telephone by
a member of the Data Coordinating Center (University of
Texas School of Public Health, Houston, Texas) to a staff
member of a clinical center at the randomization visit. The
prespecified primary outcome was defined as fatal CHD or
confirmed nonfatal MI. For analysis of the treatment effects in
subgroups, an expanded end point was used and was defined as
fatal CHD, nonfatal MI, CABG or PTCA (“combined coro-
nary events”).
Statistical analysis. All analyses were performed on an
intention to treat basis. A p value (two-tailed) ,0.05 was
considered statistically significant. Baseline characteristics in
the two treatment groups were determined using standard z
scores (18) for continuous variables and chi-square tests for
categoric variables. All hypothesis testing and all risk reduc-
tions with their confidence intervals were assessed using the
Cox proportional hazards model. Kaplan-Meier survival curves
for the control and pravastatin groups were calculated (19).
Cox proportional hazards analysis was used to assess the
relation between baseline characteristics and the occurrence of
end points. In this analysis, risk factor status was assessed at
baseline. Patients were then tracked at 3-month intervals.
The assessment of a potential difference between the
therapeutic effect in women and men was addressed by adding
an interaction term (the product of an indicator variable for
therapy and an indicator variable for gender) in a model that
included an effect for therapy and an effect for gender. If the
effect of pravastatin on the end point was different in men than
in women, this interaction term would be statistically signifi-
cant. Because a possible explanation for the statistically signif-
icant interaction might be the influence of other baseline risk
factors (e.g., previous MI, time since the index MI, baseline
LDL cholesterol or diabetes), these, as well as other baseline
risk factors, were added to this interaction model.
Results
Reasons for exclusion before randomization. The clinical
records from hospitals and ambulatory practices for a total of
11,207 patients (2,132 women [19%], 9,075 men [81%]) were
screened, and 4,159 qualified for the CARE trial. Of the 2,132
women screened, 576 (27%) qualified for the study. Women
were more likely to be excluded than men (73% vs. 61%, p ,
0.001). Baseline characteristics for exclusion differed between
women and men, respectively, as follows: 1) total cholesterol or
triglyceride levels too high (15% vs. 12%); 2) LDL cholesterol
levels too low (7% vs. 17%); and 3) criteria for MI not met
(63% vs. 54%, p , 0.001 for all comparisons). No significant
differences were found for concomitant medical conditions,
disapproval by personal physician or refusal by patient.
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CARE 5 Cholesterol and Recurrent Events
CHD 5 coronary heart disease
HDL 5 high density lipoprotein
HMG CoA 5 hydroxymethylglutaryl coenzyme A
LDL 5 low density lipoprotein
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary angioplasty
4S 5 Scandinavian Simvastatin Survival Study
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Baseline characteristics of women and men. The average
time from MI to randomization was 323 days for women and
306 days for men (p , 0.05) (Table 1). Women were older than
men at randomization (61 vs. 58 years). The prevalence at
baseline of the following risk factors was significantly greater in
women than in men, respectively: hypertension (54% vs. 41%),
diabetes (20% vs 13%), current smoking (30% vs. 20%) and
family history of CHD (45% vs. 40%). Women were more
likely than men to have multiple risk factors for CHD.
Women had a higher mean total cholesterol concentration
than men (215 vs. 208 mg/dl), resulting from a higher high
density lipoprotein (HDL) cholesterol concentration (45 vs. 38
mg/dl, p , 0.05) (Table 2). LDL cholesterol, very low density
lipoprotein cholesterol and triglyceride levels were similar in
women and men.
Fewer women than men in the CARE trial received throm-
bolytic therapy for their MI (38% vs. 43%), and fewer under-
went CABG between the time of their qualifying MI and
randomization (15% vs. 23%, p , 0.05). The use of other
coronary procedures, including angiography and PTCA, was
not significantly different. Women more frequently had evi-
dence of clinical congestive heart failure at baseline, despite a
higher mean left ventricular ejection fraction (both p , 0.05).
Therapy received at the time of randomization also differed
significantly. Fewer women than men were given aspirin (80%
vs. 84%), and beta-adrenergic blocking agents (36% vs. 41%),
whereas more received calcium channel blocking agents (46%
vs. 38%) and diuretic drugs (21% vs. 10%). Only 10% of
women were receiving estrogen replacement therapy, and only
3% progesterone, at study entry.
Effects on plasma lipids. Pravastatin had a similar effect on
plasma lipids in women and men: Averaged over 5 years, total
cholesterol was decreased by 19% to 20%, LDL cholesterol by
28%, triglycerides by 13% to 14%; HDL rose by 4% to 5%
(Table 2). The reduction in LDL was similar for the 5-year
duration.
Clinical events. Cardiovascular. The risk of a recurrent
event in the placebo-treated patients was similar in women and
Figure 1. Combined coronary events in women and men treated with
placebo.
Table 1. Baseline Characteristics of Women and Men in Cholesterol
and Recurrent Events Trial
Women
(n 5 576)
Men
(n 5 3,583)
General
Age (yr) 61* 58
Race
White 90% 93%
Other 10% 7%
Hypertension 54%* 41%
Current smoker 30%* 20%
Diabetes 20%* 13%
Body mass index (kg/m2) 28 28
Weight (kg) 71 84*
Blood pressure (mm Hg)
Systolic 134* 128
Diastolic 78 79
Family Hx of CHD 45* 40
Cardiovascular status
Q wave MI 55%* 62%
Non-Q wave MI 13%* 9%
Undetermined MI 32% 29%
Days from MI to
randomization
323* 306
Angina 27%* 20%
CHF, past Hx 10%* 7%
CABG 15%* 23%
PTCA 30% 27%
CABG or PTCA 50%* 55%
Coronary angiography 77% 79%
Thrombolysis 38%* 43%
LVEF 55%* 53%
Medications
Aspirin 80%* 84%
Beta-blocker 36%* 41%
Nitrate 36%* 32%
Ca channel blocker 46%* 38%
ACE inhibitor 16% 14%
Diuretic agent 21%* 10%
Insulin 6%* 2%
Oral hypoglycemic agent 8% 6%
Estrogen 10%* 0
*p , 0.05. Data presented are mean value or percent of patients. ACE 5
angiotensin-converting inhibitor; Ca 5 calcium; CABG 5 coronary artery bypass
graft surgery; CHD 5 coronary heart disease; CHF 5 congestive heart failure;
Hx 5 history; LVEF 5 left ventricular ejection fraction; MI 5 myocardial
infarction; PTCA 5 percutaneous transluminal coronary angioplasty.
Table 2. Plasma Lipid Concentrations in Women and Men
Plasma lipid
Women Men
mg/dl
(mean 6 SD) % Change
mg/dl
(mean 6 SD) % Change
Cholesterol
Total 215 6 15* 220† 208 6 17 219†
LDL 140 6 14 228† 139 6 15 228†
HDL 45 6 11* 14 38 6 8 15†
Triglycerides 154 6 61 213† 156 6 61 214†
*p , 0.05, women versus men at baseline. †p , 0.05. HDL 5 high density
lipoprotein; LDL 5 low density lipoprotein; % change 5 percent change in the
pravastatin versus the placebo group averaged over 5 years.
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men (Fig. 1). Women in the pravastatin group experienced an
early reduction in risk for major coronary events, with the
treatment curve beginning to separate from the placebo curve
at 1 year (Fig. 2). The overall risk reduction was 46% for
women versus 20% for men (Fig. 2, Tables 3 and 4). The test
for significance for an interaction between therapy and gender
showed a p value of 0.048 (Table 5).
Pravastatin therapy caused a substantial reduction of all
major cardiovascular events in women (Table 3): The primary
end point of CHD death or nonfatal MI was decreased by 43%
(p 5 0.035), fatal or non-fatal MI by 56% (p 5 0.009), PTCA
by 48% (p 5 0.025), CABG by 40% (p 5 0.14) and stroke by
56% (p 5 0.07). Men in the pravastatin group also showed a
significant reduction in risk for the primary and combined
coronary end points and in revascularization procedures, but
the magnitude of the reduction was lower than that in women
(Table 4).
Cancer. Cancer was reported in 12 women in the placebo
group and 23 in the pravastatin group (5 vs. 2 for gastrointes-
tinal, 1 vs. 12 for breast, 3 vs. 4 for genitourinary, 3 vs. 4 for
respiratory, 0 vs. 1 for “other,” placebo vs. pravastatin, respec-
tively). Of the 12 cases of breast cancer in the pravastatin
group, 3 occurred in patients with previous breast cancer, 1 was
ductal carcinoma in situ, and 1 occurred in a patient who took
pravastatin for only 6 weeks. The one case in the placebo group
occurred in a woman with previous breast cancer. Total cancer
occurrence in men was 133 for the placebo group and 124 for
the pravastatin group (colon 12 vs. 6, gastrointestinal 16 vs. 16,
nervous system 2 vs. 4, respiratory 35 vs. 31, genitourinary 58
vs. 56, melanoma 3 vs. 3, “other” 7 vs. 8, placebo vs. pravasta-
tin, respectively).
Discussion
The CARE trial compared the effect of pravastatin and
placebo in 576 post-MI women with average cholesterol levels
who received treatment typical of North American patients
with this condition. After an average duration of treatment of
5 years, the rates of the major coronary events were reduced by
40% to 55% in women. The risk of stroke was reduced 56% in
the pravastatin group (p 5 0.07), a new finding in women with
lipid-lowering treatment.
Paucity of information on cholesterol-lowering treatment
in women. Exclusion of women from studies of cholesterol
lowering has hampered the development of evidence-based
standards of care for women with CHD (20). The need for
Figure 2. Coronary events in women and men treated with
pravastatin or placebo (overall risk reduction: 46% for
women, 20% for men, p 5 0.001 for both).
Table 3. Cardiovascular Events in Women
Event
Placebo Group (n 5 290) Pravastatin Group (n 5 286)
% Risk
Reduction
(95% CI)
p
Value
No. of
Pts
Incidence
of Events
No. of
Pts
Incidence of
Events (%)
Death from CHD or nonfatal MI 39 13.4% 23 8.0% 43 (4 to 66) 0.035
Death from CHD 14 4.8% 11 3.8% 21 (274 to 64) 0.56
Nonfatal MI 28 9.7% 14 4.9% 51 (8 to 74) 0.028
Fatal MI 6 2.1% 1 0.3% 83 (240 to 98) 0.099
Fatal or nonfatal MI 33 11.4% 15 5.2% 56 (18 to 76) 0.009
Clinical nonfatal MI* 38 13.1% 18 6.3% 54 (20 to 74) 0.006
CABG 23 7.9% 14 4.9% 40 (217 to 69) 0.13
PTCA 34 11.7% 18 6.3% 48 (8 to 71) 0.025
CABG or PTCA 57 19.7% 28 9.8% 53 (26 to 70) 0.001
Unstable angina 65 22.4% 56 19.6% 14 (223 to 40) 0.41
Stroke 16 5.5% 7 2.4% 56 (27 to 82) 0.071
Combined coronary events† 80 27.6% 46 16.1% 46 (22 to 62) 0.001
*Reported by clinical center. †CHD death, nonfatal MI, PTCA and CABG. CI 5 confidence interval; Pts 5 patients; other abbreviations as in Table 1.
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information in women regarding the efficacy of cholesterol
treatment is compelling because cardiovascular disease is the
leading cause of death in women. Moreover, at the time the
CARE trial was designed, data from the late 1980s showed that
mortality rates from MI were higher in women than in men,
and it was suspected that this result might be related to less
aggressive care, fewer procedures and, possibly, less optimal
medication (21–26) received by women who were shown to be
at higher risk than men for complications from invasive
cardiovascular procedures (27–30). There was considerable
uncertainty as to whether gender differences reflected treat-
ment bias or appropriate clinical judgment (31). This uncer-
tainty underscored the need for effective treatments for sec-
ondary prevention in women. The CARE study had, as a
prestated goal, the inclusion of large numbers of women to
facilitate the development of evidence-based recommenda-
tions.
Enrollment of women. The ability to randomize large
numbers of women in a long-term clinical trial remained a
challenge. A large series of patients with MI showed that 26%
of those ,75 years old were women (32). In the CARE trial
with its upper age limit of 75 years, only 19% of the screened
population were women, possibly reflecting a lower proportion
of women in the CARE hospitals than reported elsewhere (33)
or perhaps reluctance of research staff to approach elderly
women (e.g., 70 to 75 years old) for participation in research
because of practical concerns related to adherence and reten-
tion; barriers such as transportation and physical limitations;
and dependence on other care givers for compliance. Whereas
19% of the screened population were women, only 14% of
randomized patients in the CARE trial were women. Review
of screening data and exclusion criteria suggests that women
were more likely to be excluded because of failure to meet the
strict MI criteria or because their total cholesterol or triglyc-
eride levels were too high. They were not excluded more often
than men for their or their physician’s disapproval of the study.
Future trials should consider the need for specific eligibility
criteria for women that reflect their inherent differences, with
the goal of enrolling a cohort of women representative of the
general female population (33).
Risk factors in women and men. There were small but
significant differences between women and men in the severity
of CHD and in CHD risk factors at baseline. These differences
include age and a higher incidence of congestive heart failure,
angina, smoking, hypertension and multiple risk factors. The
only risk factor that would favor the women was a higher HDL
cholesterol level (45 vs. 38 mg/dl), a level still low for women
and likely to contribute to their risk. Nonetheless, the inci-
dence of cardiovascular events in the placebo-treated women
was not different from that in men. Some of the risk in the early
post-MI period, which tends to be greater for women than for
men, was avoided in the CARE trial by enrolling patients at
least 3 months after MI. Perhaps the proportion of women in
the CARE trial was lowered and the subsequent event rate
modified because fewer very high risk women were random-
ized because of death or complications before screening.
Coronary events in women and men. Pravastatin treatment
significantly reduced coronary events in women as well as in
men. The percent reduction in the primary end point (CHD
Table 4. Cardiovascular Events in Men
Event
Placebo Group (n 5 1,788)
Pravastatin Group (n 5
1,799)
% Risk
Reduction
(95% CI)
p
Value
No. of
Pts
Incidence
of Events
No. of
Pts
Incidence
of Events
Death from CHD or nonfatal MI 235 13.1% 189 10.5% 21 (4 to 35) 0.017
Death from CHD 105 5.9% 85 4.7% 20 (27 to 40) 0.13
Nonfatal MI 145 8.1% 121 6.7% 18 (25 to 40) 0.11
Fatal MI 32 1.8% 23 1.3% 29 (222 to 58) 0.21
Fatal or nonfatal MI 174 9.7% 142 7.9% 20 (0 to 46) 0.05
Clinical nonfatal MI* 193 10.8% 164 9.1% 16 (23 to 32) 0.09
CABG 184 10.3% 142 7.9% 24 (5 to 39) 0.01
PTCA 185 10.3% 154 8.6% 18 (21 to 34) 0.06
CABG or PTCA 334 18.7% 266 14.8% 22 (9 to 34) 0.002
Unstable angina 294 16.4% 261 14.5% 13 (23 to 26) 0.10
Stroke 62 3.5% 47 2.6% 25 (29 to 49) 0.14
Combined coronary events† 469 26.2% 384 21.4% 20 (8 to 30) 0.001
*Reported by clinical center. †CHD death, nonfatal MI, PTCA and CABG. Abbreviations as in Tables 3 and 1.
Table 5. Test for Differential Effect of Pravastatin on Coronary
Events in Women Versus Men
Wald
Chi-
Square
p
Value RR
95% CI
Lower
Value
Upper
Value
Treatment group 10.7 0.001 0.55 0.38 0.78
Gender 0.0 0.892 0.98 0.77 1.26
Interaction* 3.9 0.048 1.48 1.00 2.18
*Denotes difference in treatment effect between women and men (p 5
0.048); results were similar whether adjustment was made for differences in
baseline characteristics between women and men. CI 5 confidence interval;
RR 5 relative risk.
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death or nonfatal MI) or in combined coronary events was
approximately twice as great in women as that in men.
However, we recommend caution in interpreting these differ-
ences because we did not hypothesize, a priori, that women
would experience more benefit than men, and the p value is
borderline (0.048) for a difference in event reduction between
women and men. Also, participants were not stratified by
gender in the randomization. Although there were minor but
significant differences in baseline characteristics between
women and men, they did not explain the difference in event
reduction. In the 4S trial, the degree of event reduction was
similar in women and men. Because a greater proportion of
women than men in the 4S trial (15) qualified for the trial by
a diagnosis of angina rather than MI, it is possible that the
effects of treatment in the women could have been diluted by
women who did not have significant structural coronary dis-
ease. The trials were also different with regard to lipid entry
criteria. The North American patients in the CARE trial also
had more medical and interventional treatments than their
Scandinavian counterparts, which could have affected the
action of cholesterol-lowering treatment. In conclusion, until
information becomes available from other trials that have
enrolled women, it remains uncertain whether there is a true
gender difference in the efficacy of cholesterol treatment in
general or in the effect of any particular agent.
Autopsy studies (34) have shown that coronary lesions are
different in women than in men, with MI in women more often
caused by plaque erosion rather than by rupture. Erosion of
endothelial cells occurs over plaque that has a predominance
of smooth muscle cells and proteoglycan rather than macro-
phage foam cells and cholesterol esters, as in plaque that is
prone to rupture. Plaque erosion also occurs in patients who
have an average rather than an elevated serum cholesterol
level (220 vs. 262 mg/dl for erosion vs. rupture, respectively)
(15). Davies (35,36) hypothesized that the results of the CARE
trial, in women with average cholesterol, indicate that choles-
terol treatment prevents thrombosis over eroded plaque. Al-
though an attractive concept, we caution that it is not known
which mechanism was responsible for the clinical coronary
events in the patients in the CARE trial—plaque erosion or
rupture—and which process was prevented by pravastatin.
Cancer incidence. Total cancer incidence was not signifi-
cantly different between the pravastatin and placebo groups. In
the men, there were no differences between the groups in
cancer incidence by site. Possible reasons for the higher
number of breast cancer cases in the women in the pravastatin
than those in the placebo group have been discussed (16) and
include a very low incidence in the placebo group (no new
cases) or an imbalance in risk factors at baseline. There is no
known biological basis for suspecting a causal link. The clearest
evidence that this finding is anomalous and due to chance
comes from the results of the Long-Term Intervention with
Pravastatin in Ischemic Disease (LIPID) trial (37), which
studied 1,508 women for 6 years after pravastatin or placebo
treatment. There was no excess of breast cancer in the
pravastatin group (Tonkin A, oral presentation, 70th Annual
Scientific Sessions of the American Heart Association, Novem-
ber 1997). Finally, the 4S trial (15) found no increase in breast
cancer in women treated with simvastatin for 5 years.
Conclusions. Women with an MI show strong, early reduc-
tion in recurrent coronary events during therapy with prava-
statin, despite having average cholesterol levels before treat-
ment. Women experienced a major reduction in risk for
coronary events and stroke of 40% to 55%, with benefit
beginning by 1 year. Treatment will prevent an extensive range
of subsequent cardiovascular events: It may be anticipated that
for every 1,000 women entered into the CARE trial and
treated for 5 years, 228 cardiovascular events would be pre-
vented (16). Physicians now have the information for evidence-
based medical practice of lipid-lowering therapy in women
with CHD, in particular, for the majority of women with
average levels of total and LDL cholesterol.
We acknowledge the efforts of members of the Gender and Age Writing Group
who contributed to the conception and writing of the report: Jane Grant, RN,
David Johnstone, MD, Gerald Timmis, MD and Barry R. Davis, MD.
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